Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
The 214-patient trial met its primary endpoint with statistical significance. Suven now pushes to global Phase 3 registrational studies.
— 3 earlier stories on Suven Life Sciences Ltd. →What's new
- Primary endpoint met: 3.6-point MADRS reduction vs placebo (p=0.038)
- Secondary endpoints on illness severity, disability, and quality of life also favoured drug
- Plan to start global Phase 3 registrational studies
Why this matters
For a company with negligible revenue and a ₹7,081 cr market cap riding on its pipeline, a positive Phase 2b de-risks Ropanicant as a novel α4β2 antagonist for the massive MDD market. But Phase 3 execution remains the real test.
What we're watching
- Phase 3 trial design and enrollment timeline
- Potential partnership interest from larger pharma
- Readouts from Suven's other CNS candidates (Samelisant, Masupirdine)
The full read
Suven's Ropanicant just did what mid-stage depression drugs need to do: beat placebo with statistical significance. In a 214-patient Phase 2b trial across 35 US sites, patients on 45 mg twice daily showed a 3.6-point greater improvement on the MADRS scale than placebo after six weeks (p=0.038). Secondary endpoints, including illness severity, disability, and quality of life, all favoured the drug. No withdrawal symptoms or dissociation after stopping. For a company with ₹2 cr in quarterly sales and a ₹7,081 cr market cap riding entirely on its pipeline, this materially de-risks a novel mechanism in a massive market. Phase 3 is the next gating event, and Suven plans global registrational studies. It won't be fast, but it's a real step.
Questions answered
- What is Ropanicant?
- Ropanicant is an experimental oral antidepressant that acts as an α4β2 nicotinic acetylcholine receptor antagonist — a novel mechanism for major depressive disorder.
- What was the Phase 2b trial design?
- It was a randomised, double-blind, placebo-controlled study enrolling 214 patients across 35 US sites. Patients received 45 mg Ropanicant twice daily or placebo for 6 weeks.
- How clinically meaningful is the 3.6-point MADRS improvement?
- The p-value of 0.038 indicates statistical significance. While 3.6 points is considered a modest to moderate effect size in MDD trials, it meets the bar for advancing to Phase 3.
- Were there any safety concerns?
- Ropanicant was well tolerated with no withdrawal symptoms or dissociation after discontinuation — a key advantage over many existing antidepressants.
- What are Suven's next steps?
- Suven plans to initiate global Phase 3 registrational studies. The company also has other ongoing CNS programmes including Samelisant (Phase 2 for narcolepsy) and Masupirdine (Phase 3 for Alzheimer's).
Suven Life Sciences Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SUVEN →- 17 Jun 2026 · 12:36 PM IST Suven's Ropanicant clears Phase 2b, cuts depression scores 3.6 points vs placebo
- 1d ago Suven's experimental cognitive drug clears Phase 1 safety hurdle
- 5d ago Suven to show Samelisant Phase 2 data at SLEEP-2026
- 13d ago Suven's Alzheimer's drug passes a critical Phase 3 safety check.